Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

29 Apr 2010 09:02

RNS Number : 0230L
e-Therapeutics plc
29 April 2010
 



e-Therapeutics plc

('e-Therapeutics' or 'the Company')

 

Issue of Equity and Director's award of Options

 

e-Therapeutics plc (AIM: ETX), the systems biology drug discovery company, announces that on 28 April 2010 , the Company issued and allotted 466,460 ordinary shares of 0.1p each in the Company (' Ordinary Shares') in order to satisfy the exercise of certain options.

 

Application has been made to admit the new Ordinary Shares to trading on AIM and dealings in the new Ordinary Shares are expected to commence on 5 May 2010. Following admission the number of Ordinary Shares in issue in the Company will be 65,886,752.

 

The above figure (65,886,752 Ordinary Shares) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the FSA's Disclosure and Transparency Rules.

 

In addition to the above, two directors of the Company being Mr Oliver James and Mr Brad Hoy were both granted option over 25,000 ordinary shares in the Company at an exercise price of £0.385 and which have a vesting period of 3 years. Following this grant Mr James and Mr Hoy have the following interests in ordinary shares of the Company:

 

Name

Ordinary Shares owned

Options over Ordinary Shares

Number

Number

Exercise Price

Date at which exercisable

Oliver James

38,500

118,020

£0.67

Vested

25,000

£0.385

28 April 2013

Brad Hoy

80,000

£0.375

Vested

25,000

£0.385

28 April 2013

 

 

 

- Ends -

 

 

For more information:

e-Therapeutics plc

www.etherapeutics.co.uk

Malcolm Young

malcolm@etherapeutics.co.uk

+44 (0) 191 233 1317

Nominated Advisor & Broker:

Canaccord Adams Ltd

www.canaccordadams.com

Robert Finlay / Henry Fitzgerald-O'Connor

henry.fitzgerald-o'connor@canaccordadams.com

+44 (0) 20 7050 6500

Media enquiries:

Abchurch Communications

www.abchurch-group.com

Heather Salmond / Simone Elviss / Hannah Sharman

simone.elviss@abchurch-group.com

+44 (0) 20 7398 7700

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOESEFSAUFSSESL
Date   Source Headline
13th Jul 201610:00 amRNSDirectorate Change
12th Jul 20168:00 amRNSIssue of Equity
21st Jun 201612:59 pmRNSIssue of Equity
7th Jun 20162:08 pmRNSIssue of Equity and Directors' shareholdings
1st Jun 20167:00 amRNSSearchbolt Offer becomes wholly unconditional
27th May 20163:18 pmRNSResult of General Meeting
25th May 20162:59 pmRNSResult of AGM
25th May 20167:00 amRNSAGM Statement
13th May 20164:08 pmRNSNotice of General Meeting - Correction
12th May 201610:50 amRNSDirector/PDMR Shareholding
11th May 20167:00 amRNSProposed Acquisition of Searchbolt, Notice of GM
15th Apr 201612:19 pmRNSNotice of AGM and Annual Report
22nd Mar 20167:00 amRNSFinal Results
4th Mar 20167:00 amRNSNotice of Results
15th Feb 20167:00 amRNSTop-line Phase IIb results update
6th Jan 20167:00 amRNSAppointment of Non-Executive Chairman
15th Dec 20153:38 pmRNSHolding(s) in Company
30th Nov 20154:48 pmRNSHolding(s) in Company
29th Oct 20157:00 amRNSAppointment of Non-Executive Director
29th Sep 20157:00 amRNSHalf Yearly Report
17th Sep 20157:05 amRNSNotice of Half Year Results
17th Sep 20157:00 amRNSChange of Nominated Adviser and Broker
10th Sep 20159:00 amRNSDirector's Disclosure
17th Aug 20157:00 amRNSHalf year trading and commercial strategy update
19th Jun 20158:38 amRNSExercise of Options
11th Jun 201511:31 amRNSResult of AGM
11th Jun 20157:00 amRNSAGM Statement
21st May 20157:00 amRNSProgress in ETS2101 Phase Ib Study
7th May 20157:00 amRNSNotice of AGM and Annual Report
31st Mar 20157:00 amRNSFinal Results
11th Mar 20154:08 pmRNSHolding(s) in Company
11th Mar 201512:41 pmRNSHolding(s) in Company
10th Mar 20157:03 amRNSNotice of Full Year Results
6th Mar 20152:22 pmRNSHolding(s) in Company
26th Feb 20151:55 pmRNSStmnt re Share Price Movement
21st Jan 201511:20 amRNSDirector/PDMR Shareholding
7th Jan 20157:00 amRNSAwards made under Performance Share Plan
7th Jan 20157:00 amRNSIssue of Equity
5th Jan 20157:00 amRNSDirectorate Change
19th Dec 20147:00 amRNSe-Therapeutics' Impact is rated World Class
18th Dec 20147:00 amRNSUpdate: ETS2101 Phase 1a and Oral Dosing Studies
27th Nov 20147:00 amRNSResearch and Development presentation to Investors
16th Oct 20148:35 amRNSAppointment of Executive Director
16th Sep 20147:00 amRNSHalf Yearly Report
4th Sep 20142:55 pmRNSNotice of Results
5th Aug 20147:00 amRNSAdditional Listing
1st Aug 20149:22 amRNSIssue of equity and Directors' shareholdings
9th Jul 201411:31 amRNSAGM Statement
9th Jul 20147:00 amRNSAwards made under Performance Share Plan
4th Jul 20147:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.